Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Receivables - Net (2019 - 2025)

Historic Receivables - Net for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $1.2 million.

  • Legend Biotech's Receivables - Net rose 7531.91% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 7531.91%. This contributed to the annual value of $6.3 million for FY2024, which is 9371.56% down from last year.
  • Latest data reveals that Legend Biotech reported Receivables - Net of $1.2 million as of Q3 2025, which was up 7531.91% from $27.6 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Receivables - Net peaked at $100.0 million during Q4 2023, and registered a low of $15000.0 during Q2 2021.
  • Moreover, its 5-year median value for Receivables - Net was $2.4 million (2021), whereas its average is $16.9 million.
  • Over the last 5 years, Legend Biotech's Receivables - Net had its largest YoY gain of 11105666.67% in 2023, and its largest YoY loss of 9988.9% in 2023.
  • Quarter analysis of 5 years shows Legend Biotech's Receivables - Net stood at $50.4 million in 2021, then tumbled by 99.82% to $90000.0 in 2022, then soared by 111056.67% to $100.0 million in 2023, then tumbled by 93.72% to $6.3 million in 2024, then plummeted by 80.34% to $1.2 million in 2025.
  • Its Receivables - Net was $1.2 million in Q3 2025, compared to $27.6 million in Q2 2025 and $369000.0 in Q1 2025.